Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1

Conditions

Colorectal Neoplasms 70Neoplasm Metastasis 20Rectal Neoplasms 19Colonic Neoplasms 17Neoplasms 11Cholangiocarcinoma 7Carcinoma, Non-Small-Cell Lung 7Head and Neck Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Carcinoma, Squamous Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Colorectal Cancer Metastatic 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Carcinoma 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Fallopian Tube Neoplasms 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Serotonin Syndrome 1Salivary Gland Malignancy 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × Panitumumab × Clear all
NCT00756444 2018-11-15

A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

Amgen

Phase 2 Completed
67 enrolled 8 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT00454779 2018-10-17

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Amgen

Phase 2 Completed
113 enrolled 18 charts

Neoplasm Metastasis, Recurrence

NCT01388621 2013-08-20

PROVE

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Unknown
140 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡